Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Argininosuccinate lyase is a cytosolic enzyme that catalyzes the reversible cleavage of argininosuccinate to produce arginine and fumarate, a critical step in the urea cycle and arginine biosynthesis[1][3][8][9]. The enzyme functions as a homotetramer, with each monomer contributing to the formation of active sites necessary for catalysis[1][2]. Deficiency or mutations in the *ASL* gene disrupt the urea cycle, leading to toxic ammonia buildup, neurological damage, and the genetic disorder argininosuccinic aciduria[3][5][7]. Argininosuccinate lyase also influences nitric oxide synthesis by supporting arginine availability, making it relevant to vascular biology[3]. Management of ASL deficiency primarily involves dietary control, ammonia-scavenging drugs, and L-arginine supplementation[3].
L-arginine supplementation provides the downstream product that is deficient in ASL deficiency, bypassing the metabolic block caused by reduced enzyme activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Argininosuccinate lyase (ASL).